MX2017001031A - Móleculas de unión a her2 y cd3 biespecíficas. - Google Patents

Móleculas de unión a her2 y cd3 biespecíficas.

Info

Publication number
MX2017001031A
MX2017001031A MX2017001031A MX2017001031A MX2017001031A MX 2017001031 A MX2017001031 A MX 2017001031A MX 2017001031 A MX2017001031 A MX 2017001031A MX 2017001031 A MX2017001031 A MX 2017001031A MX 2017001031 A MX2017001031 A MX 2017001031A
Authority
MX
Mexico
Prior art keywords
her2
methods
binding specifications
specifications
binding
Prior art date
Application number
MX2017001031A
Other languages
English (en)
Other versions
MX386342B (es
Inventor
Kong V Cheung Nai-
Lopez-Albaitero Andres
Xu Hong
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2017001031A publication Critical patent/MX2017001031A/es
Publication of MX386342B publication Critical patent/MX386342B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se proporcionan las composiciones, los métodos y usos que incluyen moléculas de unión biespecíficas que se unen específicamente a HER2, un receptor tirosina cinasa, y a CD3, un receptor de células T, y median la citotoxicidad de las células T para manejar y tratar trastornos, como puede ser el cáncer. También se proporcionan en la presente los usos y métodos para manejar y tratar cánceres relacionados con HER2.
MX2017001031A 2014-07-25 2015-07-24 Móleculas de unión a her2 y cd3 biespecíficas. MX386342B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029342P 2014-07-25 2014-07-25
PCT/US2015/041989 WO2016014942A1 (en) 2014-07-25 2015-07-24 Bispecific her2 and cd3 binding molecules

Publications (2)

Publication Number Publication Date
MX2017001031A true MX2017001031A (es) 2017-05-04
MX386342B MX386342B (es) 2025-03-18

Family

ID=53836217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001031A MX386342B (es) 2014-07-25 2015-07-24 Móleculas de unión a her2 y cd3 biespecíficas.

Country Status (15)

Country Link
US (3) US10519248B2 (es)
EP (1) EP3172236B1 (es)
JP (1) JP6871155B2 (es)
KR (1) KR102638104B1 (es)
CN (1) CN107124884B (es)
AU (1) AU2015292374B2 (es)
BR (1) BR112017001513A2 (es)
CA (1) CA2956014C (es)
ES (1) ES2832704T3 (es)
IL (1) IL250249B (es)
MX (1) MX386342B (es)
RU (1) RU2017105849A (es)
SG (1) SG11201700506TA (es)
WO (1) WO2016014942A1 (es)
ZA (1) ZA201701341B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA129760C2 (uk) 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
US10519248B2 (en) 2014-07-25 2019-12-31 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US11046768B2 (en) * 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CA3051484A1 (en) * 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
KR20190140943A (ko) * 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
JP7475275B2 (ja) 2018-02-08 2024-04-26 ジェネンテック， インコーポレイテッド 二重特異性抗原結合分子及びその使用方法
CA3093694A1 (en) * 2018-03-12 2019-09-19 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
CR20200459A (es) * 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
IL279399B1 (en) * 2018-06-14 2026-04-01 Bioatla Llc Multispecific antibody templates
CA3118397A1 (en) * 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
WO2020113164A1 (en) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
WO2020123642A1 (en) * 2018-12-11 2020-06-18 The Translational Genomics Research Institute Identification of her2 mutations in lung cancer and methods of treatment
AU2020225631A1 (en) 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CN113874399B (zh) * 2019-05-23 2025-07-11 维洛斯生物股份有限公司 抗ror1/抗cd3双特异性结合分子
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体
WO2021119505A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
EP4126954A4 (en) * 2020-03-23 2024-08-21 Cytoarm Co. Ltd. BISPECIFIC ANTIBODIES FOR USE IN THE PRODUCTION OF ARMED IMMUNE CELLS
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US20230270857A1 (en) * 2020-07-28 2023-08-31 Memorial Sloan Kettering Cancer Center Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
US20230374150A1 (en) * 2020-10-12 2023-11-23 Memorial Sloan Kettering Cancer Center Anti-psma antibodies and uses thereof
KR20230100732A (ko) 2020-11-04 2023-07-05 제넨테크, 인크. 항-cd20/항-cd3 이중특이성 항체의 피하 투여
AU2021374594B2 (en) 2020-11-04 2026-03-05 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023014810A2 (en) * 2021-08-04 2023-02-09 Abpro Corporation Anti-her2 antibodies and uses thereof
US20240415888A1 (en) * 2021-10-20 2024-12-19 Memorial Sloan Kettering Cancer Center Anti-tshr multi-specific antibodies and uses thereof
KR102803655B1 (ko) 2021-12-29 2025-05-08 건국대학교 글로컬산학협력단 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
KR102857671B1 (ko) 2021-12-29 2025-09-10 건국대학교 글로컬산학협력단 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
CA3247048A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE
EP4658326A2 (en) * 2023-02-04 2025-12-10 Imagion Biosystems, Inc. Method to assess nodal disease using iron oxide nanoparticles in magnetic resonance imaging
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof
WO2025085781A1 (en) 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
WO2010099536A2 (en) 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Engineered proteins with high affinity for dota chelates
CN114805583A (zh) * 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
DK3323830T3 (da) * 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
HUE045348T2 (hu) * 2011-05-08 2019-12-30 Legochem Biosciences Inc Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
EP2723380B1 (en) * 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
EP2748340B1 (en) * 2011-11-02 2016-06-01 Ajinomoto Co., Inc. Method for secretory production of proteins
EP2895203A4 (en) * 2012-06-15 2016-09-28 Imaginab Inc ANTIGENBINDING CONSTRUCTS FOR CD3
CN104271602B (zh) * 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
WO2015095404A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
US10519248B2 (en) 2014-07-25 2019-12-31 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
CA3051484A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules

Also Published As

Publication number Publication date
JP2017527274A (ja) 2017-09-21
KR20170038835A (ko) 2017-04-07
MX386342B (es) 2025-03-18
ES2832704T3 (es) 2021-06-11
EP3172236B1 (en) 2020-09-30
AU2015292374A1 (en) 2017-03-16
SG11201700506TA (en) 2017-02-27
NZ729286A (en) 2023-12-22
JP6871155B2 (ja) 2021-05-12
KR102638104B1 (ko) 2024-02-20
IL250249B (en) 2021-04-29
US11987642B2 (en) 2024-05-21
BR112017001513A2 (pt) 2018-02-14
EP3172236A1 (en) 2017-05-31
CN107124884B (zh) 2022-11-01
ZA201701341B (en) 2021-05-26
US20200199248A1 (en) 2020-06-25
AU2015292374B2 (en) 2020-09-03
US10519248B2 (en) 2019-12-31
CA2956014A1 (en) 2016-01-28
IL250249A0 (en) 2017-03-30
CN107124884A (zh) 2017-09-01
US20260071005A1 (en) 2026-03-12
CA2956014C (en) 2023-10-31
RU2017105849A (ru) 2018-08-29
US20170210819A1 (en) 2017-07-27
WO2016014942A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
MX2017001031A (es) Móleculas de unión a her2 y cd3 biespecíficas.
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
MX2019009848A (es) Proteínas que se unen a her2, nkg2d y cd16.
MX2017005553A (es) Terapia de combinacion para cancer.
ECSP18011248A (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
MX387463B (es) Moléculas de unión a antígeno biespecíficas activadoras de células t y antagonistas de unión al eje de pd-1 y usos de los mismos para el tratamiento de cáncer.
UY36862A (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
CL2014003355A1 (es) Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros.
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
ES3060467T3 (en) Anti-pd-l1/pd-1 combinations for treating tumors
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
MX387487B (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton.
CO2017003005A2 (es) Anticuerpos anti-mfi2
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
MX373280B (es) Anticuerpos anti-egfrviii y usos de los mismos.
MX2017014375A (es) Moduladores del ccr2.
CO2017000065A2 (es) Indoles funcionalizados y sustituidos como agentes anti-cáncer
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata